Varian Biopharmaceuticals, Inc. and SPK Acquisition Corp. Announce Release of Investor Presentation Regarding Previously Announced Merger; Provide Corporate Update

Author's Avatar
Feb 28, 2022

NAPLES, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. (“Varian Bio”), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. (“SPK”) (NASDAQ: SPK), a special purpose acquisition company (“SPAC”), today announced a joint presentation to discuss the proposed transaction and provide a corporate update.